The FDA has approved suzetrigine, branded as Journavx, a new class of painkiller effective for moderate-to-severe pain from injuries or surgeries. Unlike traditional pain relievers such as opioids or aspirin, suzetrigine operates on nerves outside the brain, minimizing addictive potential and side effects. Its approval follows successful clinical trials that demonstrated its efficacy in alleviating post-surgical pain without the adverse effects typical of opioid medications. Experts hailed the approval as a major breakthrough in pain management, potentially benefiting millions of patients relying on acute pain relief with reduced risks.
Today's approval is a historic milestone for the 80 million people in America who are prescribed a medicine for moderate-to-severe acute pain each year.
Suzetrigine is not intended to replace opioid medications in their entirety. Rather it can offer a relatively (relative to opioids) risk-free way of managing pain acutely.
Collection
[
|
...
]